HAIC Combined With Targeted Therapy and Immunotherapy as Down-stage Therapy of LT
Status:
Not yet recruiting
Trial end date:
2028-07-30
Target enrollment:
Participant gender:
Summary
This is a prospective single center, open-label, non-randomized, single arm exploratory
study. The objective of this study is to evaluate the efficacy and safety of HAIC combined
with targeted therapy and immunotherapy as down-stage therapy for hepatocellular carcinoma
before liver transplantation.
Phase:
Phase 2
Details
Lead Sponsor:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University